Although a role for α7nAChRs in the etiology of AD has not been established, many animal studies have demonstrated cognitive enhancing effects of compounds targeting α7nAChRs [102], including the α7nAChR partial agonist EVP-6124, which has also been shown to enhance cognition in patients with mild to moderate AD [103]. This evidence concerns the gene CHRNA7 and Alzheimer disease.